Enanta Pharma Stock (NASDAQ:ENTA), Trade Ideas

Enanta Pharma

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ABVC

AIRE

ALZN

ANGH

AORT

ATGL

BURL

CENT

COMP

ENTA

FINV

GANX

GLMD

GPAK

HIBB

JAGX

MCAF

Morgan Stanley Capital Protected Notes for S&P 500 Index

MRAI

RCEL

SBSW

SKIN

TCOM

TCON

VTVT

XXII

Shares of American Eagle Outfitters, Inc. (NYSE: AEO) declined during Tuesday’s session after the company reported third-quarter financial results.

Net revenue rose 5% Y/Y to $1.30 billion, beating the consensus of $1.28 billion. EPS of $0.49 surpassed the consensus of $0.48.

Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

ABNB

ADTX

ADXN

ALBT

AMTI

ARAV

AWIN

AXLA

BCDA

BTTR

CABA

CBIO

CBUS

CLRB

CRKN

CRMT

CXAI

EDBL

EEIQ

EFSH

EGHT

FUBO

GETY

HRYU

HSDT

INSM

MANU

NTGR

NVOS

NXGN

OLMA

QURE

RMAX

SNDL

UPTD

VERB

WORX

ZLAB

Gainers


	Verb Technology Company, Inc.  (NASDAQ: VERB) shares jumped 164% to $1.89 after the completed and launched a technology integration and strategic relationship with global social media platform TikTok.


Why America&#39;s Car-Mart Are Trading Lower By 12%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Earnings

Guidance

Pre-Market Outlook

AXSM

BIIB

CHGG

COIN

DDOG

DKNG

FIVN

GENI

SOVO


	Piper Sandler raised the price target for  Chegg, Inc.  (NYSE: CHGG) from $11 to $13. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Chegg shares rose 19.9% to $12.03 in pre-market trading.


DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharmaceuticals Inc

Entain PLC

JP Morgan analyst Eric Joseph maintains Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) with a Underweight and lowers the price target from $12 to $11.

Price Target

Analyst Ratings

JP Morgan Maintains Underweight on Enanta Pharma, Lowers Price Target to $11

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) reported its Q1 earnings results on Wednesday, February 7, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Enanta Pharma missed estimated earnings by 32.77%, reporting an EPS of $-1.58 versus an estimate of $-1.19.
Revenue was down $5.58 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.67 which was followed by a 11.52% increase in the share price the next day.
Here's a look at Enanta Pharma's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-2</td>
<td>-2.33</td>
<td>-1.98</td>
<td>-1.59</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.33</td>
<td>-1.86</td>
<td>-1.79</td>
<td>-1.39</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>17.50M</td>
<td>18.06M</td>
<td>19.18M</td>
<td>22.57M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>18.93M</td>
<td>18.89M</td>
<td>17.80M</td>
<td>23.59M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Enanta Pharma <a href="https://www.benzinga.com/quote/ENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Enanta Pharma Q1 Earnings

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) reported quarterly losses of $(1.58) per share which missed the analyst consensus estimate of $(1.23) by 28.46 percent. This is a 13.67 percent decrease over losses of $(1.39) per share from the same period last year. The company reported quarterly sales of $18.00 million which missed the analyst consensus estimate of $21.95 million by 17.97 percent. This is a 23.67 percent decrease over sales of $23.59 million the same period last year.

Earnings Misses

Enanta Pharma Q1 2024 GAAP EPS $(1.58) Misses $(1.23) Estimate, Sales $18.00M Miss $21.95M Estimate

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-02-07. Here's what investors need to know before the announcement.
Analysts estimate that Enanta Pharma will report an earnings per share (EPS) of $-1.19. 
Enanta Pharma bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.67, which was followed by a 11.52% increase in the share price the next day.
Here's a look at Enanta Pharma's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-2</td>
<td>-2.33</td>
<td>-1.98</td>
<td>-1.59</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.33</td>
<td>-1.86</td>
<td>-1.79</td>
<td>-1.39</td>
</tr>
<tr>
<td>Price Change %</td>
<td>11.52%</td>
<td>-4.24%</td>
<td>-25.66%</td>
<td>-3.54%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1707242533_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Enanta Pharma were trading at $12.37 as of February 05. Over the last 52-week period, shares are down 75.66%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/ENTA/earnings">To track all earnings releases for Enanta Pharma visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Enanta Pharma

<ul>
<li>Expansion into Immunology with New Discovery Program of Oral KIT Inhibitors Addressing High Unmet Need in Chronic Spontaneous Urticaria (CSU); Development Candidate Selection Targeted for 2024</li>
<li>Expect Topline Data from at Least One Phase 2 Study of Zelicapavir (EDP-938), an N-Protein Inhibitor in Development to Treat Respiratory Syncytial Virus (RSV), in 3Q 2024, Pending Continuation of a Normal Northern Hemisphere RSV Season</li>
<li>Anticipate Challenge Study Data for EDP-323, an L-Protein Inhibitor in Development to Treat RSV, in 3Q 2024</li>
</ul>

Enanta Pharmaceuticals Will Provide An Update Across Its Pipeline And Plans For 2024 At The 42nd Annual J.P. Morgan Healthcare Conference On Wednesday, January 10, 2024

Jay Luly, President and CEO at Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>), reported a large acquisition of company stock options on November 22, according to a new SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001177648/000106299323021379//Archives/edgar/data/1177648/000106299323021379/0001062993-23-021379-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that Luly, President and CEO at Enanta Pharma, a company in the Health Care sector, was just awarded stock options worth 264,000 shares of ENTA. The options give Luly the right to buy the company's stock at $8.99 per share.
Enanta Pharma shares are trading down 11.53% at $8.82 at the time of this writing on Thursday morning. Since the current price is $8.82, this makes Luly's 264,000 shares worth $2,328,480.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001177648">Check Out The Full List Of Enanta Pharma's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Enanta Pharma President and CEO Awarded $2.33M Worth of Stock Options

Oppenheimer analyst Jay Olson maintains Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) with a Perform and lowers the price target from $25 to $21.

Oppenheimer Maintains Perform on Enanta Pharma, Lowers Price Target to $21

WIIM

Enanta Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 revenue results.

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) has observed the following analyst ratings within the last quarter: 
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
These 5 analysts have an average price target of $28.8 versus the current price of Enanta Pharma at $9.18, implying upside.
Below is a summary of how these 5 analysts rated Enanta Pharma over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock
<img src="https://www.benzinga.com/files/images/story/2023/1700575214_0.png" alt="price target chart" />
This current average has decreased by 20.55% from the previous average price target of $36.25. 
<a href="https://www.benzinga.com/quote/ENTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Enanta Pharma analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h1>What Are Analyst Ratings?</h1>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 5 Analyst Ratings Have To Say About Enanta Pharma

HC Wainwright &amp; Co. analyst Ed Arce maintains Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) with a Buy and lowers the price target from $30 to $28.

HC Wainwright & Co. Maintains Buy on Enanta Pharma, Lowers Price Target to $28

JMP Securities analyst Roy Buchanan maintains Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) with a Outperform and lowers the price target from $42 to $23.

JMP Securities Maintains Outperform on Enanta Pharma, Lowers Price Target to $23

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) reported its Q4 earnings results on Monday, November 20, 2023 at 04:01 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Enanta Pharma beat estimated earnings by 33.5%, reporting an EPS of $-1.33 versus an estimate of $-2.0.
Revenue was down $1.39 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.47 which was followed by a 4.24% drop in the share price the next day.
Here's a look at Enanta Pharma's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-2.33</td>
<td>-1.98</td>
<td>-1.59</td>
<td>-1.35</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.86</td>
<td>-1.79</td>
<td>-1.39</td>
<td>-1.27</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>18.06M</td>
<td>19.18M</td>
<td>22.57M</td>
<td>22.86M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>18.89M</td>
<td>17.80M</td>
<td>23.59M</td>
<td>20.32M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Enanta Pharma <a href="https://www.benzinga.com/quote/ENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Enanta Pharma Q4 Earnings

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) reported quarterly losses of $(1.33) per share. This is a 4.72 percent decrease over losses of $(1.27) per share from the same period last year. The company reported quarterly sales of $18.93 million which beat the analyst consensus estimate of $17.50 million by 8.18 percent. This is a 6.83 percent decrease over sales of $20.32 million the same period last year.

Enanta Pharma Q4 EPS $(1.33) Vs. $(1.27) Last Year, Sales $18.93M Beat $17.50M Estimate

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) is set to give its latest quarterly earnings report on Monday, 2023-11-20. Here's what investors need to know before the announcement.
Analysts estimate that Enanta Pharma will report an earnings per share (EPS) of $-2.00. 
Enanta Pharma bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.47, which was followed by a 4.24% drop in the share price the next day.
Here's a look at Enanta Pharma's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-2.33</td>
<td>-1.98</td>
<td>-1.59</td>
<td>-1.35</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.86</td>
<td>-1.79</td>
<td>-1.39</td>
<td>-1.27</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.24%</td>
<td>-25.66%</td>
<td>-3.54%</td>
<td>-2.07%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2023/1700229690_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Enanta Pharma were trading at $8.69 as of November 15. Over the last 52-week period, shares are down 81.27%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/ENTA/earnings">To track all earnings releases for Enanta Pharma visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Enanta Pharma Earnings Preview

Within the last quarter, Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) has observed the following analyst ratings: 
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the last 3 months, 8 analysts have offered 12-month price targets for Enanta Pharma. The company has an average price target of $31.38 with a high of $48.00 and a low of $15.00. 
Below is a summary of how these 8 analysts rated Enanta Pharma over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock
<img src="https://www.benzinga.com/files/images/story/2023/1698076829_0.png" alt="price target chart" />
This current average has decreased by 27.7% from the previous average price target of $43.40. 
<a href="https://www.benzinga.com/quote/ENTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Enanta Pharma analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h1>How Are Analyst Ratings Determined?</h1>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations for Enanta Pharma's Future

HC Wainwright &amp; Co. analyst Ed Arce maintains Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) with a Buy and lowers the price target from $48 to $30.

HC Wainwright & Co. Maintains Buy on Enanta Pharma, Lowers Price Target to $30

Within the last quarter, Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) has observed the following analyst ratings: 
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
These 6 analysts have an average price target of $34.33 versus the current price of Enanta Pharma at $12.47, implying upside.
Below is a summary of how these 6 analysts rated Enanta Pharma over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock
<img src="https://www.benzinga.com/files/images/story/2023/1695139222_0.png" alt="price target chart" />
This current average has decreased by 28.48% from the previous average price target of $48.00. 
<a href="https://www.benzinga.com/quote/ENTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Enanta Pharma analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h1>Analyst Ratings: What Are They?</h1>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings for Enanta Pharma

HC Wainwright &amp; Co. analyst Ed Arce reiterates Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) with a Buy and maintains $48 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $48 Price Target

Enanta Pharmaceuticals To Present EDP-323 Data For Respiratory Syncytial Virus Treatment At 9th ESWI Influenza Conference

<h3>Gainers</h3>
<ul>
<li>First Wave BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWBI#NASDAQ">FWBI</a>) stock increased by 136.2% to $0.69 during Tuesday's regular session. Trading volume for this security as of 13:30 EST is 37.4 million, which is 2106.0% of its average full-day volume over the last 100 days. The company's market cap stands at $4.8 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock rose 47.69% to $10.9. Trading volume for Helius Medical Tech's stock is 18.1 million as of 13:30 EST. This is 45643.0% of its average full-day volume over the last 100 days. The company's market cap stands at $6.1 million. </li>
<li>Novo Integrated Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVOS#NASDAQ">NVOS</a>) stock rose 40.0% to $0.3. The current volume of 178.0 million shares is 631.4% of Novo Integrated Sciences's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $47.4 million. </li>
<li>Orgenesis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGS#NASDAQ">ORGS</a>) shares rose 38.79% to $0.81. As of 13:30 EST, Orgenesis's stock is trading at a volume of 229.5K, which is 280.6% of its average full-day volume over the last 100 days. The company's market cap stands at $24.5 million. </li>
<li>Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) shares moved upwards by 30.78% to $19.5. Cibus's stock is trading at a volume of 158.6K shares as of 13:30 EST. This is 197.5% of its average full-day volume over the last 100 days. The company's market cap stands at $324.5 million. </li>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) shares moved upwards by 30.72% to $1.08. Akso Health Group's stock is trading at a volume of 511.3K shares as of 13:30 EST. This is 379.8% of its average full-day volume over the last 100 days. The company's market cap stands at $24.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) stock decreased by 29.3% to $0.55 during Tuesday's regular session. The current volume of 280.8K shares is 301.5% of BioCardia's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $11.9 million. </li>
<li>Acer Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACER#NASDAQ">ACER</a>) shares fell 16.54% to $0.95. The current volume of 1.4 million shares is 63.9% of Acer Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $23.2 million. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) shares fell 16.34% to $2.1. The company's market cap stands at $13.1 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares fell 15.99% to $2.68. As of 13:30 EST, this security is trading at a volume of 865.0K shares, making up 31.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $32.0 million. </li>
<li>Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) stock decreased by 15.41% to $12.47. Trading volume for Enanta Pharma's stock is 656.8K as of 13:30 EST. This is 283.2% of its average full-day volume over the last 100 days. The company's market cap stands at $262.5 million. </li>
<li>Vanda Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) shares declined by 15.37% to $4.33. As of 13:30 EST, this security is trading at a volume of 3.2 million shares, making up 535.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $248.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACER

FRES

FWBI

ORGS

VNDA

12 Health Care Stocks Moving In Tuesday's Intraday Session

Roanna Ruiz, an analyst from Leerink Partners, maintained the Hold rating on Enanta Pharmaceuticals (ENTA – Research Report). The associated price ...

Maintaining Hold on Enanta Pharmaceuticals Amid Near-Term Challenges and Pipeline Potential

Oppenheimer analyst Jay Olson maintained a Hold rating on Enanta Pharmaceuticals (ENTA – Research Report) today and set a price target of $17.00. T...

Oppenheimer Keeps Their Hold Rating on Enanta Pharmaceuticals (ENTA)

Enanta Pharmaceuticals Inc (ENTA) stock has gained 11.25% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator. Enanta Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ENTA!See Full ENTA ReportWhat is Stock Sentiment

Is Enanta Pharmaceuticals Inc (ENTA) a Stock to Watch After Gaining 11.25% This Week?

Enanta Pharmaceuticals (ENTA) has shared an update. At Enanta's recent Annual Meeting, shareholders cast their votes on several key proposals. They...

Enanta Pharmaceuticals Shareholders Affirm Management Direction

Liver drug developers outperform as U.S. awaits first NASH drug

Madrigal and liver drug developers fall ahead of FDA decision on NASH therapy

Madrigal granted FDA approval for NASH therapy

Madrigal climbs amid hopes for new NASH drug; B. Riley upgrades

Inventiva Phase 2 study for MASH drug meets primary endpoint

Enanta Pharmaceuticals Inc (ENTA) stock has fallen -67.34% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives ENTA stock a score of  26 out of a possible 100. That rank is chiefly influenced by a short-term technical score of 7. ENTA's r

Should You Hold Enanta Pharmaceuticals Inc (ENTA) Stock Tuesday?

AKRO

ARWR

ASCLF

ETNB

GALT

GILD

HEPA

IONS

MDGL

NONOF

SGMT

TERN

VKTX

Press Releases

Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET

Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference

Enanta Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023

Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET

Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Akebia Therapeutics

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Erasca

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals